• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$52.63 $0.96 (1.86%)

REAL-TIME: Last trade at

Express Scripts, Inc.

NASDAQ:ESRX

Can Express Scripts Manage Its Debt?

Hedge Funds' Top 10 Stocks: For This They Get Two-and-Twenty?

Humana Pharmacy Unit Seeks Customers Amid Industry Changes

Avoid the PBM Space -- for Now

Why Did I Break Up With Him? Walgreens Probably Wants Ex-BF Express Scripts Back

Hedge Fund Stock Picks: Whale Hunting of the Kingmakers

CVS Reiterated at Neutral - Analyst Blog

Walgreen's Loss Is CVS's Gain

Earnings Miss at Express Scripts - Analyst Blog

Express Scripts Strikes Bullish Tone As Selling Season Picks Up

Express Scripts Holding Misses Where It Counts

Stocks Headed Higher as Bargain Hunters Emerge

Express Scripts 1Q Down 18% As Expenses Rise, Revenue Up

UPDATE: Express Scripts 1Q Profit Declines On Medco Costs

24/7 Wall St. Closing Bell (AIG, COP, HSY, PSX, DMD, AOL, AGU, DTG, M, MPEL, TM, SODA, AMCX, MT, ESR

ESRX Loss Hurts Walgreen Again - Analyst Blog

Will CVS Caremark Help You Retire Rich?

How High Can CVS Caremark Fly?

2nd UPDATE: CVS Caremark 1Q Profit Rises 8.8%; Raises Fiscal Year View

CORRECT: UPDATE: CVS Caremark 1Q Profit Rises 8.8%; Raises Fiscal Year View

Strong 1Q for CVS, Guidance Up - Analyst Blog

5 stocks picked by billionaires

CVS Caremark Targets Opportunity In Filling Medicare Part D’s Doughnut Hole

CVS Caremark Earnings Wednesday To Show Pharmacy Benefits Mgt. Turnaround

This Sector Favors No Investor

Will Walgreen Help You Retire Rich?

AmerisourceBergen Posts Modest 2Q - Analyst Blog

TIP SHEET: Janus Fund Tries To Manage Risk Of Drug Stocks

Catalyst Health Stays Neutral - Analyst Blog

Express Scripts Seeks Bids For Potential $20 Billion/Year Contract

All Is Not Rite With This Company

Healthways Runs into Loss, Revs Up - Analyst Blog

Judge Denies Bid To Halt Express Scripts-Medco Merger

TIP SHEET: Janus Fund Tries To Manage Risk Of Drug Stocks

2nd UPDATE: UnitedHealth's Profits Rise As Membership Climbs

Catalyst, SXC surge on merger disclosure

2 Dominant Health-Care Stocks to Buy Today

CVS on the Horizon

3rd UPDATE: Drug Plan Manager SXC To Buy Catalyst For $4.14 Billion

2nd UPDATE: Drug Plan Manager SXC To Buy Catalyst For $4.14 Billion

See More Articles...